Enpatoran HCl | CAS#2409589-21-3 | TLR7/8 inhibitor

MedKoo Cat#: 463684 | Name: Enpatoran HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enpatoran, also known as M5049, is a novel potent and selective TLR7/8 inhibitor for treatment of autoimmunity. M5049 showed potent and selective activity in a range of cellular assays for inhibition of TLR7/8 and block synthetic ligands and natural endogenous RNA ligands such as microRNA and Alu RNA. M5049 was found to be potent in vivo as TLR7/8 inhibition efficaciously treated disease in several murine lupus models. M5049 had greater potency in disease models than expected based on its in vitro potency and pharmacokinetic/pharmacodynamic properties. M5049 may be efficacious in treating autoimmunity and has the potential to provide benefit to a variety of patients with varying disease pathogenesis.

Chemical Structure

Enpatoran HCl

CAS#2409589-21-3 (2HCl)

Theoretical Analysis

MedKoo Cat#: 463684

Name: Enpatoran HCl

CAS#: 2409589-21-3 (2HCl)

Chemical Formula: C16H17Cl2F3N4

Exact Mass: 0.0000

Molecular Weight: 393.24

Elemental Analysis: C, 48.87; H, 4.36; Cl, 18.03; F, 14.49; N, 14.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2101945-93-9 (HCl) 2409589-21-3 (2HCl) 2101938-42-3 (free base) 2409588-96-9 (TFA)

Synonym

M5049; M 5049; M-5049; Enpatoran; Enpatoran 2HCl; Enpatoran dihydrochloride;

IUPAC/Chemical Name

5-((3R,5S)-3-amino-5-(trifluoromethyl)piperidin-1-yl)quinoline-8-carbonitrile, dihydrochloride

InChi Key

XXUSUJYZCUAXIE-UVDYRLMLSA-N

InChi Code

InChI=1S/C16H15F3N4.2ClH/c17-16(18,19)11-6-12(21)9-23(8-11)14-4-3-10(7-20)15-13(14)2-1-5-22-15;;/h1-5,11-12H,6,8-9,21H2;2*1H/t11-,12+;;/m0../s1

SMILES Code

N#CC1=C2N=CC=CC2=C(N3C[C@H](N)C[C@H](C(F)(F)F)C3)C=C1.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Toll-like receptor (TLR) 7 and TLR8 are transmembrane receptors that recognize single-stranded RNA. Activation of these receptors results in immune cell stimulation and inflammatory cytokine production, which is normally a protective host response. However, aberrant activation of TLR7/8 is potentially pathogenic and linked to progression of certain autoimmune diseases such as lupus.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 393.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Modell SM, Bayer IS, Kardia SLR, Morales CJ, Adler I, Greene-Moton E. Health in Our Hands: diabetes and substance use education through a new genomic framework for schools and communities. J Community Genet. 2023 Jan 16:1–15. doi: 10.1007/s12687-022-00631-x. Epub ahead of print. PMID: 36645618; PMCID: PMC9841132. 2: Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, Mammasse N, Ona V, Bachmann A, Strugala D, Reh C, Goteti K. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol Res Perspect. 2021 Oct;9(5):e00842. doi: 10.1002/prp2.842. PMID: 34414672; PMCID: PMC8377444. 3: Vlach J, Bender AT, Przetak M, Pereira A, Deshpande A, Johnson TL, Reissig S, Tzvetkov E, Musil D, Morse NT, Haselmayer P, Zimmerli SC, Okitsu SL, Walsky RL, Sherer B. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity. J Pharmacol Exp Ther. 2021 Mar;376(3):397-409. doi: 10.1124/jpet.120.000275. Epub 2020 Dec 16. PMID: 33328334. 4: Modell SM, Fleming PJ, Lopez WD, Goltz HH. Work in Progress: Immigrant Health Care from the Vantage of Cancer Testing and Screening. J Immigr Minor Health. 2021 Feb;23(1):1-3. doi: 10.1007/s10903-020-01129-9. Epub 2020 Nov 24. PMID: 33231790. 5: Modell SM, Kardia SLR. Religion as a Health Promoter During the 2019/2020 COVID Outbreak: View from Detroit. J Relig Health. 2020 Oct;59(5):2243-2255. doi: 10.1007/s10943-020-01052-1. PMID: 32548832; PMCID: PMC7297133.